Manufacturer: NovoNordisk

VICTOZA (Liraglutide)      

VICTOZA (Liraglutide)      

Used for: Treatment of Type 2 DM in combination with oral treatments for T2DM (Metformin, Sulfonylureas, Pioglitazone, etc.) and/or basal insulin (Insulatard, Humulin I, Levemir, Glargine et.c) when these, in combination or alone, are not sufficient to achieve adequate blood glucose control.

Monotherapy License: No

Insulin License: Yes

Dose: 0.6mg daily for at least one week, to be increased to 1.2mg daily. Maximum treatment dose 1.8mg daily.

Side Effects

Very common: nausea, diarrhoea. 

Common: hypoglycaemia, vomiting, bloating , diarrhoea, upper abdominal pain, constipation, flatulence, headache, dizziness, fatigue, toothache, gastroesophageal reflux, rash, injection site reactions. 

Uncommon: dehydration, changes in renal function (renal failure).

Renal impairment: Not recommended if Cr clearance is < 30ml/min.

Pregnancy and lactation: Stop before pregnancy, do not use during pregnancy. Do not use while breast feeding.

Contraindications: Allergy to any of the ingredients. In addition to this, in the US, also a past medical history or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Hyperplasia Type 2 (MEN 2). If a patient develops pancreatitis while taking this medication, do not restart the medication after the episode of pancreatitis.